Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

S. Ramalingam, Suresh; Vansteenkiste, Johan; Planchard, David; Chul Cho, Byoung; E. Gray, Jhanelle; Ohe, Yuichiro; Zhou, Caicun; Reungwetwattana, Thanyanan; Cheng, Ying; Chewaskulyong, Busyamas; Shah, Riyaz; Cobo, Manuel; Hyeong Lee, Ki; Cheema, Parneet; Tiseo, Marcello; John, Thomas; Lin, Meng‐Chih; Imamura, Fumio; Kurata, Takayasu; Todd, Alexander; Hodge, Rachel; Saggese, Matilde; Rukazenkov, Yuri; Soria, Jean‐Charles

doi:10.1056/nejmoa1913662

Public

Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Published in New England Journal of Medicine • Nov 21, 2019

Authors:

Suresh S. Ramalingam

Johan Vansteenkiste

David Planchard

Abstract

BACKGROUND: Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in pa...

Subject

Osimertinib

T790M

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!